Literature DB >> 6617716

Effect of the orally absorbed dopamine analogue N-methyldopamine diisobutyric ester on plasma prolactin levels.

G Lombardi, A Tommaselli, C Fariello, A Quattrone, L Annunziato.   

Abstract

The effect of the diisobutyric ester of N-methyldopamine (Ibopamine) on plasma prolactin levels was investigated in normoprolactinaemic subjects and in hyperprolactinaemic patients with prolactin-secreting tumours or idiopathic hyperprolactinaemia. In hyperprolactinaemic states oral Ibopamine 50 mg induced a significant decrease in elevated plasma prolactin (PRL) levels, 30, 60 and 90 min after administration. The peak effect occurred at 90 min when the mean PRL level was 61% of its basal values.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6617716     DOI： 10.1007/bf00544029

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  8 in total

Review 1.  Prolactin.

Authors:  A G Frantz
Journal:  N Engl J Med       Date:  1978-01-26       Impact factor: 91.245

2.  Renal effect of SB 7505: a double-blind study.

Authors:  G F Melloni; G M Minoja; G Scorazzati; R Bauer; B Brusoni; P Ghirardi
Journal:  Eur J Clin Pharmacol       Date:  1981-02       Impact factor: 2.953

3.  Regulation of the tuberoinfundibular and nigrostriatal systems. Evidence for different kinds of dopaminergic neurons in the brain.

Authors:  L Annunziato
Journal:  Neuroendocrinology       Date:  1979       Impact factor: 4.914

4.  Effects of dopamine infusion on pituitary hormone secretion in humans.

Authors:  H Leblanc; G C Lachelin; S Abu-Fadil; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1976-09       Impact factor: 5.958

5.  Effectiveness of ibopamine in the management of ascitic liver cirrhosis--a controlled study v placebo and frusemide.

Authors:  G F Melloni; G M Minoja; R Melloni; E Piatto; E Scarazzati; R Bauer; P Ghirardi
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

6.  Clinical tolerability of ibopamine hydrochloride (SB 7505).

Authors:  G F Melloni; R Melloni; G M Minoja; G Scarazzati; G C Bruni; P Loreti; R Bauer
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

7.  Noninvasive evaluation of the effects of oral ibopamine (SB 7505) on cardiac and renal function in patients with congestive heart failure.

Authors:  L Dei Cas; C Manca; B Bernardini; G Vasini; O Visioli
Journal:  J Cardiovasc Pharmacol       Date:  1982 May-Jun       Impact factor: 3.105

8.  Ibopamine (SB 7505) in normal subjects and in chronic renal failure: a preliminary report.

Authors:  S Stefoni; L Colì; G Mosconi; R Prandini
Journal:  Br J Clin Pharmacol       Date:  1981-01       Impact factor: 4.335
  8 in total
  4 in total

1.  Inhibition of prolactin and aldosterone secretion by the dopamine derivative ibopamine.

Authors:  E Rolandi; G Marchetti; R Franceschini; V Cicchetti; R Gianrossi; V Cantoni; T Barreca
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 2.  Drug-induced changes in prolactin secretion. Clinical implications.

Authors:  K Hell; H Wernze
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

Review 3.  Ibopamine. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.

Authors:  J M Henwood; P A Todd
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

4.  Ibopamine-induced reduction of serum prolactin level and milk secretion in puerperal women.

Authors:  C Nappi; G Colace; P Affinito; M Taglialatela; G F Di Renzo; U Montemagno; L Annunziato
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.